Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
B-cell malignancies
BCMA
CAR-T cells
CD19
immunotherapy
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
24 Feb 2020
24 Feb 2020
Historique:
received:
14
12
2019
revised:
16
02
2020
accepted:
19
02
2020
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
28
2
2020
Statut:
epublish
Résumé
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
Identifiants
pubmed: 32102267
pii: pharmaceutics12020194
doi: 10.3390/pharmaceutics12020194
pmc: PMC7076393
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Biotechnol. 2018 Oct;36(9):847-856
pubmed: 30102295
Vox Sang. 1998;74 Suppl 2:321-9
pubmed: 9704463
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Hematol Oncol. 2019 Jun;37 Suppl 1:48-52
pubmed: 31187535
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Front Oncol. 2019 Mar 12;9:146
pubmed: 30915277
Blood. 2013 Feb 28;121(9):1612-21
pubmed: 23247726
Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Best Pract Res Clin Haematol. 2018 Jun;31(2):147-157
pubmed: 29909915
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
Front Immunol. 2019 Nov 12;10:2664
pubmed: 31798590
J Clin Oncol. 2017 Sep 10;35(26):3010-3020
pubmed: 28715249
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Blood. 2019 Nov 7;134(19):1585-1597
pubmed: 31558469
Blood. 2016 Jun 23;127(25):3225-36
pubmed: 27127303
Mol Ther Oncolytics. 2019 Aug 28;15:60-68
pubmed: 31650026
Trends Immunol. 2005 Feb;26(2):111-7
pubmed: 15668127
Sci Transl Med. 2019 Jul 3;11(499):
pubmed: 31270272
Clin Transl Immunology. 2019 May 11;8(5):e1049
pubmed: 31110702
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Front Immunol. 2019 Jul 16;10:1613
pubmed: 31379824
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Ann Hematol. 2019 Apr;98(4):813-822
pubmed: 30693373
Nat Med. 2019 Sep;25(9):1408-1414
pubmed: 31477906
J Exp Med. 1998 Aug 17;188(4):619-26
pubmed: 9705944
Blood. 2019 Dec 12;134(24):2149-2158
pubmed: 31697826
Hematology Am Soc Hematol Educ Program. 2012;2012:143-51
pubmed: 23233573
Front Oncol. 2019 Aug 19;9:767
pubmed: 31482064
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Mol Ther Oncolytics. 2016 Apr 20;3:16011
pubmed: 27626062
Lancet Haematol. 2019 Oct;6(10):e521-e529
pubmed: 31378662
Sci Transl Med. 2019 Mar 27;11(485):
pubmed: 30918115
Clin Cancer Res. 2012 Nov 15;18(22):6155-68
pubmed: 22988056
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Nat Rev Drug Discov. 2015 Jul;14(7):499-509
pubmed: 26129802
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
J Immunother Cancer. 2019 Aug 1;7(1):202
pubmed: 31370892
Immunol Rev. 2019 Jul;290(1):39-59
pubmed: 31355492
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551
pubmed: 30988175
Bone Marrow Transplant. 2019 Aug 30;:
pubmed: 31471571
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
Nature. 2019 Dec;576(7786):293-300
pubmed: 31802004
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669947
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Biomark Res. 2017 Jun 24;5:22
pubmed: 28652918
Blood. 2004 Jan 15;103(2):689-94
pubmed: 14512299
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Mol Cancer Ther. 2019 Mar;18(3):498-506
pubmed: 30824581
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Oncoimmunology. 2018 Aug 6;8(10):e1271857
pubmed: 31646067
Adv Cell Gene Ther. 2019 Jul;2(3):
pubmed: 31777773
Mol Cancer Ther. 2018 Sep;17(9):1795-1815
pubmed: 30181329
Nat Commun. 2019 Jul 17;10(1):3137
pubmed: 31316055
Cancer Cell. 2017 Mar 13;31(3):396-410
pubmed: 28262554
J Clin Oncol. 2017 Jun 1;35(16):1803-1813
pubmed: 28291388
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
J Clin Invest. 2019 Mar 12;129(5):2123-2132
pubmed: 30860496
Clin Cancer Res. 2016 Apr 15;22(8):1875-84
pubmed: 27084741
Front Immunol. 2018 Aug 10;9:1821
pubmed: 30147690
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Am Soc Clin Oncol Educ Book. 2018 May 23;38:e6-e15
pubmed: 30231373
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
J Immunother. 2020 Jan 02;:
pubmed: 31899702
Lancet Oncol. 2020 Feb;21(2):e104-e116
pubmed: 32007196
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630